Literature DB >> 33301029

MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus.

Elizabeth Bulaeva1,2, Davide Pellacani1, Naoto Nakamichi1, Colin A Hammond1,2, Philip A Beer1,3, Alireza Lorzadeh4, Michelle Moksa4, Annaïck Carles4, Misha Bilenky5, Sylvain Lefort1, Jeremy Shu1, Brian T Wilhelm6,7, Andrew P Weng1, Martin Hirst4,5, Connie J Eaves1,2,8.   

Abstract

Hematopoietic clones with leukemogenic mutations arise in healthy people as they age, but progression to acute myeloid leukemia (AML) is rare. Recent evidence suggests that the microenvironment may play an important role in modulating human AML population dynamics. To investigate this concept further, we examined the combined and separate effects of an oncogene (c-MYC) and exposure to interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), and stem cell factor (SCF) on the experimental genesis of a human AML in xenografted immunodeficient mice. Initial experiments showed that normal human CD34+ blood cells transduced with a lentiviral MYC vector and then transplanted into immunodeficient mice produced a hierarchically organized, rapidly fatal, and serially transplantable blast population, phenotypically and transcriptionally similar to human AML cells, but only in mice producing IL-3, GM-CSF, and SCF transgenically or in regular mice in which the cells were exposed to IL-3 or GM-CSF delivered using a cotransduction strategy. In their absence, the MYC+ human cells produced a normal repertoire of lymphoid and myeloid progeny in transplanted mice for many months, but, on transfer to secondary mice producing the human cytokines, the MYC+ cells rapidly generated AML. Indistinguishable diseases were also obtained efficiently from both primitive (CD34+CD38-) and late granulocyte-macrophage progenitor (GMP) cells. These findings underscore the critical role that these cytokines can play in activating a malignant state in normally differentiating human hematopoietic cells in which MYC expression has been deregulated. They also introduce a robust experimental model of human leukemogenesis to further elucidate key mechanisms involved and test strategies to suppress them.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33301029     DOI: 10.1182/blood.2020006374

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Predictive values of plasma TNFα and IL-8 for intracranial hemorrhage in patients with acute promyelocytic leukemia.

Authors:  Fangyi Dong; Li Chen; Chaoxian Zhao; Xiaoyang Li; Yun Tan; Huan Song; Wen Jin; Hongming Zhu; Yunxiang Zhang; Kai Xue; Junmin Li; Kankan Wang
Journal:  Front Med       Date:  2022-09-12       Impact factor: 9.927

Review 2.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

3.  Construction of circRNA-Based ceRNA Network to Reveal the Role of circRNAs in the Progression and Prognosis of Hepatocellular Carcinoma.

Authors:  Rong Deng; Xiaohan Cui; Yuxiang Dong; Yanqiu Tang; Xuewen Tao; Shuyu Wang; Jincheng Wang; Lin Chen
Journal:  Front Genet       Date:  2021-02-26       Impact factor: 4.599

4.  Tumor suppressor function of WT1 in acute promyelocytic leukemia.

Authors:  Matthew J Christopher; Casey D S Katerndahl; Hayley R LeBlanc; Tyler T Elmendorf; Vaishali Basu; Margery Gang; Andrew J Menssen; David H Spencer; Eric J Duncavage; Shamika Ketkar; Lukas D Wartman; Sai Mukund Ramakrishnan; Christopher A Miller; Timothy J Ley
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

Review 5.  Inflammatory Cytokines Shape an Altered Immune Response During Myeloid Malignancies.

Authors:  Virginia Camacho; Valeriya Kuznetsova; Robert S Welner
Journal:  Front Immunol       Date:  2021-11-03       Impact factor: 7.561

6.  The role of E2A in ATPR-induced cell differentiation and cycle arrest in acute myeloid leukaemia cells.

Authors:  Meiju Zhang; Long-Fei Wang; Xiaoling Xu; Yan Du; Lanlan Li; Ge Deng; Yubin Feng; Ziyao Ou; Ke Wang; Yayun Xu; Xiaoqing Peng; Feihu Chen
Journal:  J Cell Mol Med       Date:  2022-01-09       Impact factor: 5.310

Review 7.  Chromosomal Instability in Acute Myeloid Leukemia.

Authors:  Mateus de Oliveira Lisboa; Paulo Roberto Slud Brofman; Ana Teresa Schmid-Braz; Aline Rangel-Pozzo; Sabine Mai
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

8.  Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy.

Authors:  Haibin Wu; Liyu Zhang; Zeen Zhu; Chenxi Ding; Shengquan Chen; Ruiping Liu; Huafeng Fan; Yang Chen; Hui Li
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.